Insulin-specific vaccination for type 1 diabetes: A step closer?

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 6, 2012, Pages 834-837

  Harrison, Leonard C ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Insulin; Prevention; T cell; Type 1 diabetes; Vaccination

Indexed keywords

INSULIN; PLACEBO;

ANTIDIABETIC ACTIVITY; BLOOD GLUCOSE MONITORING; CD4 LYMPHOCYTE COUNT; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENETIC PREDISPOSITION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; NONOBESE DIABETIC MOUSE; NOTE; PRIMARY PREVENTION; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; TH1 TH2 BALANCE; VACCINE PRODUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN; VACCINATION;

EID: 84863696341     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19673     Document Type: Note

References (24)

1. Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 1999; 73:153-264; PMID:10399007; http://dx.doi.org/10. 1016/S0065-2776(08)60787-7.
2. Harrison LC, Hafler DA. Antigen-specific therapy for autoimmune disease. Curr Opin Immunol 2000; 12:704-11; PMID:11102776; http://dx.doi.org/10.1016/ S0952-7915(00)00166-7.
3. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003; 3:223-32; PMID:12658270; http://dx.doi.org/10.1038/nri1029.
4. Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 2006; 116:3258-65; PMID:17143333; http://dx.doi.org/10.1172/JCI29602.
5. Narendran P, Mannering SI, Harrison LC. Proinsulin-a pathogenic autoantigen in type 1 diabetes. Autoimmun Rev 2003; 2:204-10; PMID:12848947; http://dx.doi.org/10.1016/S1568-9972(03)00009-0.
6. Zhang L, Nakayama M, Eisenbarth GS. Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol 2008; 20:111-8; PMID:18178393; http://dx.doi.org/10.1016/j.coi.2007.11.005.
7. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23:447-85; PMID:15771578; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115643.
8. Harrison LC. Risk assessment, prediction and prevention of type 1 diabetes. Pediatr Diabetes 2001; 2:71-82; PMID:15016201; http://dx.doi.org/10. 1034/j.1399-5448.2001.002002071.x.
9. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45:926-33; PMID:8666144; http://dx.doi.org/10.2337/diabetes.45.7.926.
10. Bingley PJ, Williams AJ, Gale EA. Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials. Diabetes Care 1999; 22:1796-801; PMID:10546010; http://dx.doi.org/10.2337/ diacare.22.11.1796.
11. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346:1685-91; PMID:12037147; http://dx.doi.org/10.1056/NEJMoa012350.
12. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005; 28:1068-76; PMID:15855569; http://dx.doi.org/10.2337/diacare.28.5.1068.
13. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009; 360:1646-54; PMID:19369670; http://dx.doi.org/10.1056/NEJMra0808284.
14. Chaillous L, Lefèvre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Lancet 2000; 356:545-9; PMID:10950231; http://dx.doi.org/10.1016/S0140-6736(00)02579-4.
15. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crinò A, et al.; IMDIAB Group. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). Diabetologia 2000; 43:1000-4; PMID:10990077; http://dx.doi.org/10.1007/s001250051482.
16. Hänninen A, Braakhuis A, Heath WR, Harrison LC. Mucosal antigen primes diabetogenic cytotoxic T-lymphocytes regardless of dose or delivery route. Diabetes 2001; 50:771-5; PMID:11289041; http://dx.doi.org/10.2337/ diabetes.50.4.771.
17. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996; 184:2167-74; PMID:8976172; http://dx.doi.org/10.1084/ jem.184.6.2167.
18. Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004; 27:2348-55; PMID:15451899; http://dx.doi.org/10.2337/ diacare.27.10.2348.
19. Parish CR. Immune deviation: a historical perspective. Immunol Cell Biol 1996; 74:449-56; PMID:8912008; http://dx.doi.org/10.1038/icb.1996.75.
20. Husby S, Mestecky J, Moldoveanu Z, Holland S, Elson CO. Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol 1994; 152:4663-70; PMID:8157979.
21. Waldo FB, van den Wall Bake AWL, Mestecky J, Husby S. Suppression of the immune response by nasal immunization. Clin Immunol Immunopathol 1994; 72:30-4; PMID:8020191; http://dx.doi.org/10.1006/clin.1994.1103.
22. Fourlanos S, Perry C, Gellert SA, Martinuzzi E, Mallone R, Butler J, et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 2011; 60:1237-45; PMID:21307076; http://dx.doi.org/10.2337/db10-1360.
23. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008; 372:1746-55; PMID:18814906; http://dx.doi.org/10.1016/S0140-6736(08)61309-4.
24. Achenbach P, Barker J, Bonifacio E; Pre-POINT Study Group. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 2008; 8:87-93; PMID:18445349; http://dx.doi.org/10.1007/s11892-008-0017-y.